Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27Kip1 in the cyclin E–cdk2 complexes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“Cyclin D1 is a known oncogene (Sherr, 1996), and an important key element in cell cycle progression.”
BackgroundNew functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142 · cited 1×
“This supports the suggestion that p21 promotes complex assembly and is essential for its kinase activity (Cheng et al., 1999; LaBaer et al., 1997; Zhang et al., 1994).”
BackgroundSherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980 · cited 1×
“It is welldocumented that growth factors a ect the cell cycle apparatus primarily during G1 phase, and that the main components acting as growth factor sensors are the D-type cyclins (Sherr, 1995).”
Background
Cited by
Carotenoid actions and their relation to health and disease
Krinsky, N. I., & Johnson, E. J. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.10.001 · Cited by 1,420
The biosynthesis and nutritional uses of carotenoids
Fraser, P. (2004) · Progress in Lipid Research · doi:10.1016/j.plipres.2003.10.002 · Cited by 1,375
Bioactivity and protective effects of natural carotenoids
Stahl, W., & Sies, H. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.12.006 · Cited by 898
Carotenoids: biochemistry, pharmacology and treatment
Milani, A., Basirnejad, M., Shahbazi, S., & Bolhassani, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13625 · Cited by 781
“It also decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins (Nahum et al., 2001).”
BackgroundPlant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
Cancer Chemoprevention Through Dietary Antioxidants: Progress and Promise
Khan, N., Afaq, F., & Mukhtar, H. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1740 · Cited by 591
Cancer Chemoprevention by Carotenoids
Tanaka, T., Shnimizu, M., & Moriwaki, H. (2012) · Molecules · doi:10.3390/molecules17033202 · Cited by 589
Wang, H., Oo Khor, T., Shu, L., Su, Z.-Y., Fuentes, F., Lee, J.-H., & Tony Kong, A.-N. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012803833026 · Cited by 529
Bioactivities of phytochemicals present in tomato
Chaudhary, P., Sharma, A., Singh, B., & Nagpal, A. K. (2018) · Journal of Food Science and Technology · doi:10.1007/s13197-018-3221-z · Cited by 352
Carotenoids activate the antioxidant response element transcription system
Ben-Dor, A., Steiner, M., Gheber, L., Danilenko, M., Dubi, N., Linnewiel, K., Zick, A., Sharoni, Y., & Levy, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.177.4.1 · Cited by 319
Self-citationCollins, E. J., Bowyer, C., Tsouza, A., & Chopra, M. (2022) · Biology · doi:10.3390/biology11020239 · Cited by 293
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.003 · Cited by 290
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
Chemistry and Biotechnology of Carotenoids
Namitha, K. K., & Negi, P. S. (2010) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2010.499811 · Cited by 252
Mein, J. R., Lian, F., & Wang, X.-D. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00120.x · Cited by 191
“120 In addition to ACR, the activity of other lycopene metabolites has been investigated.”
Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1
Nahum, A., Zeller, L., Danilenko, M., Prall, O. W. J., Watts, C. K. W., Sutherland, R. L., Levy, J., & Sharoni, Y. (2006) · European Journal of Nutrition · doi:10.1007/s00394-006-0595-x · Cited by 99
Self-citationMcLaughlin, J. M., Olivo-Marston, S., Vitolins, M. Z., Bittoni, M., Reeves, K. W., Degraffinreid, C. R., Schwartz, S. J., Clinton, S. K., & Paskett, E. D. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0329 · Cited by 22
Metadata
- Authors
- Nahum, A., Hirsch, K., Danilenko, M., Watts, C. K., Prall, O. W., Levy, J., & Sharoni, Y.
- Venue
- Oncogene
- Published
- 2001-06-07
- Volume
- 20
- Issue
- 26
- Pages
- 3428-3436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1964084914
- Cited by
- 235
- References
- 4
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.